Skip to main content

Peer Review reports

From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Original Submission
29 Nov 2018 Submitted Original manuscript
17 Jan 2019 Reviewed Reviewer Report - Shuangshuang Fu
21 Jan 2019 Reviewed Reviewer Report - Alice Dragomir
19 Feb 2019 Author responded Author comments - Huan Deng
Resubmission - Version 2
19 Feb 2019 Submitted Manuscript version 2
24 Feb 2019 Reviewed Reviewer Report - Alice Dragomir
8 Mar 2019 Reviewed Reviewer Report - Shuangshuang Fu
12 Mar 2019 Author responded Author comments - Huan Deng
Resubmission - Version 3
12 Mar 2019 Submitted Manuscript version 3
30 Mar 2019 Author responded Author comments - Huan Deng
Resubmission - Version 4
30 Mar 2019 Submitted Manuscript version 4
22 Apr 2019 Author responded Author comments - Huan Deng
Resubmission - Version 5
22 Apr 2019 Submitted Manuscript version 5
5 May 2019 Author responded Author comments - Huan Deng
Resubmission - Version 6
5 May 2019 Submitted Manuscript version 6
Publishing
10 May 2019 Editorially accepted
23 May 2019 Article published 10.1186/s12885-019-5704-3

You can find further information about peer review here.

Back to article page